|1.||Kahn, Michael: 8 articles (01/2015 - 08/2004)|
|2.||Nguyen, Cu: 4 articles (03/2012 - 08/2004)|
|3.||Liu, Youhua: 2 articles (01/2015 - 09/2011)|
|4.||Nie, Jing: 2 articles (01/2015 - 09/2011)|
|5.||Hao, Sha: 2 articles (01/2015 - 09/2011)|
|6.||Hou, Fan Fan: 2 articles (01/2015 - 09/2011)|
|7.||Li, Yingjian: 2 articles (01/2015 - 09/2011)|
|8.||Zhou, Beiyun: 2 articles (03/2012 - 08/2010)|
|9.||Borok, Zea: 2 articles (03/2012 - 08/2010)|
|10.||Ma, Hong: 2 articles (02/2011 - 08/2004)|
01/01/2015 - "Fibrolasts treated with TGF-β1 and ICG-001 released medium from scaffolds were used to evaluate the anti-fibrosis effect through immunofluorescence, real time PCR and western blot. "
07/01/2013 - "PKF118-310 and ICG-001 were effective in inhibiting TGF-β receptor I-driven fibrosis as assessed by the same outcome measures. "
07/01/2013 - "Blockade of canonical Wnt signalling by PKF118-310 and ICG-001 showed antifibrotic effects in different models of skin fibrosis. "
08/10/2010 - "Administration of ICG-001 concurrent with bleomycin prevents fibrosis, and late administration is able to reverse established fibrosis and significantly improve survival. "
08/10/2010 - "We report here that ICG-001 (5 mg/kg per day) significantly inhibits beta-catenin signaling and attenuates bleomycin-induced lung fibrosis in mice, while concurrently preserving the epithelium. "
|2.||Pulmonary Fibrosis (Hamman Rich Syndrome)
03/02/2012 - "We previously demonstrated that ICG-001, a small molecule specific inhibitor of the β-catenin/CBP (but not β-catenin/p300) interaction, ameliorates and reverses pulmonary fibrosis and inhibits TGF-β1-mediated α-smooth muscle actin (α-SMA) and collagen induction in AEC. "
08/10/2010 - "Because aberrant activation of the Wnt/beta-catenin signaling cascade occurs in lungs of patients with IPF, we have targeted this pathway for intervention in pulmonary fibrosis using ICG-001, a small molecule that specifically inhibits T-cell factor/beta-catenin transcription in a cyclic AMP response-element binding protein binding protein (CBP)-dependent fashion. "
07/01/2014 - "To test the hypothesis that inhibition of β-catenin signaling is beneficial in promoting alveolar and vascular development and preventing PH in experimental BPD, we examined the effects of ICG001, a newly developed pharmacological inhibitor of β-catenin, in preventing hyperoxia-induced BPD in neonatal rats. "
07/01/2014 - "Furthermore, administering ICG001 decreased PASMC proliferation and expression of extracellular matrix remodeling molecules in vitro under hyperoxia. "
07/01/2014 - "Treatment with ICG001 significantly increased alveolarization and reduced pulmonary vascular remodeling and PH during hyperoxia. "
07/01/2014 - "Primary human pulmonary arterial smooth muscle cells (PASMCs) were cultured in RA or hyperoxia (95% O2) in the presence of DMSO or ICG001 for 24 to 72 hours. "
07/01/2014 - "ICG001 (10 mg/kg) or DMSO was given by daily intraperitoneal injection for 14 days during continuous exposure to RA or hyperoxia. "
01/01/2015 - "ICG-001 was also found to restore the expression of a tumor suppressive microRNA-145 (miR-145). "
01/01/2015 - "ICG-001 also inhibited C666-1 tumor sphere formation, accompanied with reduced SOX2(hi)/CD44(hi) CSC-like population. "
01/01/2015 - "Here, we investigated whether the targeting of this pathway with a novel pharmacological inhibitor ICG-001 would result in an anti-tumor effect and improvement of chemosensitivity in MM. As expected, ICG-001 specifically down-regulated β-catenin/TCF-mediated transcription in MM cells. "
02/01/2011 - "Therefore, we believe that the ability of ICG-001 to block both the CBP/γ-catenin interaction and the CBP/β-catenin interaction may have clinical significance in cancers in which γ-catenin plays a significant transcriptional role."
11/01/2013 - "A specific small molecule inhibitor of CBP/catenin dependent transcription, ICG-001, can reverse these effects further demonstrating the critical involvement of CBP/catenin signaling in enhancing and maintaining the leukemia stem/initiating-like cell population under hypoxic conditions."
04/24/2014 - "Importantly, ICG-001, regardless of CBP mutational status and chromosomal aberration, leads to eradication of drug-resistant primary leukemia in combination with conventional therapy in vitro and significantly prolongs the survival of NOD/SCID mice engrafted with primary ALL. "
|6.||Plasminogen Activator Inhibitor 1
|7.||Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)
|8.||Transforming Growth Factors (Transforming Growth Factor)
|1.||Heterologous Transplantation (Xenotransplantation)